Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 26, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the completion of its previously announced underwritten public offering of 8,214,286 shares of its common stock at a price to the public of $70.00 per share, including 1,071,428 shares sold
View HTML
Toggle Summary Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 23, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics .
View HTML
Toggle Summary Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 23, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Seattle Genetics .
View HTML
Toggle Summary Seattle Genetics Reports Second Quarter 2019 Financial Results
-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology - BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 16, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ,
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019
BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 2, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and
View HTML
Toggle Summary Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 12, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of
View HTML
Toggle Summary Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 10, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration ( FDA ) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug
View HTML
Toggle Summary Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lymphoma Analyses Describe ADCETRIS Activity in T-Cell and B-Cell Non-Hodgkin Lymphomas Across All Levels of CD30
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
- First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO
View HTML